Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer.

doi:10.1007/s00439-026-02854-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer.

Human genetics - 29 Aug 2026

Vlaming Michiel, Kiemeney Lambertus A L M, Koole Wouter, van Oort Inge M, Bleiker Eveline M A, Ausems Margreet G E M, Frederix Geert W J

Abstract excerpt

Identifying pathogenic germline variants in men with metastatic prostate cancer is important for therapeutic options and for identifying relatives who may have a high cancer risk. To keep genetic testing costs manageable, it is important to identify which patients should be selected for testing. In this study, we compared expected costs and number of identified pathogenic variants in two scenarios: offering...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Genetic Counseling
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ-Line Mutation

Share to Health Care Costs

Share to Neoplasm Metastasis

Share to Netherlands

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42667419
DOI: 10.1007/s00439-026-02854-1
PMCID: PMC13526062

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.